madman
Super Moderator
Hitting the nail on the head here!
* The panel unpacks why “normal ranges” don’t fit every individual, highlighting genetic differences in androgen receptor sensitivity (CAG repeats) and the need to tailor treatment to symptoms and biology rather than numbers alone.
4:20-6:07
* so we have been developing a blood test which is a testosterone CAG repeat ratio. So the higher your testosterone and your lower your CAG repeat you will have a higher sensitivity of androgenization. So that's how you can work it out. We've also shown that when testosterone is given, if someone has a high CAG repeat, which is low sensitivity, they don't respond unless you get the testosterone in the HIGHER NORMAL RANGE.
At the Longevity Forum Science Summit, this testosterone panel dives into the so-called “manopause,” testosterone replacement therapy (TRT), and what the latest evidence really tells us about safety, cancer risk, and healthy ageing in men. Moderated by Professor Justin Stebbing, the discussion tackles long-standing fears around prostate cancer, explores why current data do not support TRT as a driver of prostate cancer in appropriately screened men, and explains how careful monitoring (including PSA and hematocrit) is essential. The panel unpacks why “normal ranges” don’t fit every individual, highlighting genetic differences in androgen receptor sensitivity (CAG repeats) and the need to tailor treatment to symptoms and biology rather than numbers alone. They also address the darker side of high-dose anabolic use—from infertility and delayed sperm recovery to cardiovascular concerns—and offer a clear, clinically grounded view on when TRT can help, when it harms, and how to think about hormones, lifestyle, obesity, and disease as part of a broader strategy for men’s health and longevity.
* The panel unpacks why “normal ranges” don’t fit every individual, highlighting genetic differences in androgen receptor sensitivity (CAG repeats) and the need to tailor treatment to symptoms and biology rather than numbers alone.
4:20-6:07
* so we have been developing a blood test which is a testosterone CAG repeat ratio. So the higher your testosterone and your lower your CAG repeat you will have a higher sensitivity of androgenization. So that's how you can work it out. We've also shown that when testosterone is given, if someone has a high CAG repeat, which is low sensitivity, they don't respond unless you get the testosterone in the HIGHER NORMAL RANGE.
At the Longevity Forum Science Summit, this testosterone panel dives into the so-called “manopause,” testosterone replacement therapy (TRT), and what the latest evidence really tells us about safety, cancer risk, and healthy ageing in men. Moderated by Professor Justin Stebbing, the discussion tackles long-standing fears around prostate cancer, explores why current data do not support TRT as a driver of prostate cancer in appropriately screened men, and explains how careful monitoring (including PSA and hematocrit) is essential. The panel unpacks why “normal ranges” don’t fit every individual, highlighting genetic differences in androgen receptor sensitivity (CAG repeats) and the need to tailor treatment to symptoms and biology rather than numbers alone. They also address the darker side of high-dose anabolic use—from infertility and delayed sperm recovery to cardiovascular concerns—and offer a clear, clinically grounded view on when TRT can help, when it harms, and how to think about hormones, lifestyle, obesity, and disease as part of a broader strategy for men’s health and longevity.
